Foresite Capital Portfolio
13F Holdings & Position Changes — Last filed May 15, 2026
13F Holdings & Position Changes — Last filed May 15, 2026
Foresite Capital is a $4B biotech-focused hedge fund managed by Jim Tananbaum, MD. As of their latest 13F filing (Q1 2026), the fund holds 8 positions worth $237.1M. This quarter they initiated 1 new position and exited 7. Their largest holding is PHVS ($135.0M).
Foresite initiated 1 new position and increased 2 this quarter. Portfolio grew +15.6% to $237.1M. 32 upcoming catalysts across holdings.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
No charge for 14 days · Cancel anytime
Foresite Capital held 8 biotech stocks in their 13F portfolio this quarter. Their top positions include PHVS, CYTK, EIKN, LYEL, RLAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Foresite Capital's tracked biotech portfolio is worth $237.1M across 8 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
Foresite Capital initiated 1 new position this quarter, including EIKN. They also increased 2 existing positions.
Foresite Capital fully exited 7 positions this quarter, including NTRA, KURA, SNDX, CBAY, QSIAW and 2 more. They also trimmed 1 existing positions.
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
| 1,943,682 |
| $20.6M |
| 4 | LYEL | Increased | 800,399 | $16.1M |
| 5 | RLAY | 1,000,000 | $9.9M |
| 6 | XENE | 160,000 | $9.3M |
| 7 | ALEC | 3,887,200 | $8.4M |
| 8 | MAZE | Decreased | 156,901 | $4.7M |
| Q3 2025 |
| $182.6M |
| +47.5% |
| Q2 2025 | $123.8M | +11.5% |
| Q1 2025 | $111.1M | -99.9% |
| Q4 2024 | $108.8B | +71004.2% |
| Q3 2024 | $153.0M | +2.8% |
| Q2 2024 | $148.8M | -13.6% |
| Q1 2024 | $172.2M | -1.6% |
| Q4 2023 | $175.0M | +5.1% |
| Q3 2023 | $166.5M | -4.4% |
| Q2 2023 | $174.1M | +31.6% |
| Q1 2023 | $132.3M | +398.7% |
| Q3 2022 | $26.5M | — |